I'm a pro baker, and these Presidents' Day kitchen deals are making me salivate
Henckels 20-Piece Knife Set for $160 (was $440): All-time low
Keurig K-Express Essentials Single-Serve Coffee Maker for $35 (was $59): Rare sale
Cuisinart Air Fryer Toaster Oven for $100 (was $134): All-time low
HexClad 6-Piece Hybrid Fry Pan Set for $330 (was $532): Over $200 off; Gordon Ramsay-approved
Stanley IceFlow Flip Straw 2.0 for $28 (was $45): All-time low
Anyone who's ever tried to slice through a slippery tomato with a dull knife knows just how tedious (and hazardous) that can be. If it's time for a blade swap, this No. 1 bestselling Henckels 20-piece set is down to its lowest price of all time. Trying to cut down on the amount of plastic in your kitchen? These food storage containers are made of heavy-duty glass, and they're just $40 for a 12-pack. And if you want a speedier way to brew your morning joe, the Keurig K-Express Essentials coffee maker is on sale for a mere $35.
There's more where those came from, so keep scrolling to see what else you can score for a steal. And be sure to check back in — I'll be updating this list throughout the week as more deals become available. Happy saving!
The reviews quoted above reflect the most recent versions at the time of publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
8 hours ago
- Indianapolis Star
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Click here to register Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Thursday, August 14, 2025, at 8:30 a.m. Eastern to review second-quarter 2025 financials and provide corporate updates. Participation Instructions for Jaguar Investor Webcast When: Thursday, August 14, 2025 at 8:30 AM Eastern Time Participant Registration & Access Link: Click Here Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference When: Wednesday, August 20, 2025 from 2:55 – 3:05 PM Eastern Time Where: Online (Click Here) Registration link for conference: Click Here Replay: An archived webcast of the presentation will be made available on and on the Emerging Growth YouTube Channel. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi ® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding the expectation that Jaguar will file its 10-Q on August 14, 2025 for the quarter ended June 30, 2025, the expectation that Jaguar will hold an investor webcast on August 14, 2025, and Jaguar's expectation that Jaguar management will present at the August 2025 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Yahoo
12 hours ago
- Yahoo
DOE taps 10 advanced reactor companies for expedited nuclear pilot
This story was originally published on Utility Dive. To receive daily news and insights, subscribe to our free daily Utility Dive newsletter. Dive Brief: The U.S. Department of Energy on Tuesday selected 11 advanced reactor projects to participate in a nuclear pilot program that aims to expedite deployment without Nuclear Regulatory Commission licensing, according to a June request for applications. DOE wants to achieve criticality of at least three test reactors using an expedited authorization process by July 4, 2026. Oklo and its Atomic Alchemy subsidiary were selected to develop three of the projects. DOE 'is opening the door to the market so new ideas, new approaches, and new designs can be built more quickly and efficiently,' Oklo CEO Jacob DeWitte said in a statement. Dive Insight: DOE unveiled its reactor pilot program in June, building on a May executive order signed by President Donald Trump that reformed reactor testing. The program aims to expedite testing of reactor designs authorized by DOE and located outside of the national laboratories. DOE cited the Atomic Energy Act's authorization of reactors under the agency's 'sufficient control,' in authorizing the pilot. 'Reactors built and operated pursuant to the DOE pilot program will not require Nuclear Regulatory Commission licensing,' the June request for applications said. 'Nevertheless, DOE-approved reactor designs can and will be fast tracked for future NRC licensing. ... [The pilot will] provide a fast track to an NRC license, and hence, commercialization for authorized reactor design.' DOE on Tuesday named 10 companies that could access a 'fast-tracked approach to future commercial licensing activities.' They are: Aalo Atomics; Antares Nuclear; Atomic Alchemy; Deep Fission; Last Energy; Oklo; Natura Resources; Radiant Industries; Terrestrial Energy; and Valar Atomics. Each company will be responsible for all costs associated with designing, manufacturing, constructing, operating, and decommissioning their test reactors, the DOE said. 'Seeking DOE authorization provided under the Atomic Energy Act will help today's selected companies ... unlock private funding and provide a fast-tracked approach to future commercial licensing activities,' it said in a release. DOE Deputy Secretary of Energy James Danly said in a statement that the agency will 'do everything we can' to support the companies' aim of 'safely' achieving criticality by July 4, 2026. 'This shows that the DOE is ushering in a new era of building new nuclear in America by unleashing its unique capabilities to enable American nuclear innovators to build,' Oklo's DeWitte said. 'DOE's selection of a number of projects provides a sweeping injection of urgency to meet the moment.' DOE tapped Oklo for two projects and its subsidiary, Atomic Alchemy, was selected for a third. Oklo completed its acquisition of the radioisotope producer in March. While nuclear boosters have hailed DOE's pilot program, critics say the lack of NRC licensing requirements creates safety risks. Edwin Lyman, director of nuclear power safety at the Union of Concerned Scientists, in May criticized the White House's plan to move nuclear reactor siting, licensing and fuel supply for some projects outside the NRC. 'By fatally compromising the independence and integrity of the NRC, and by encouraging pathways for nuclear deployment that bypass the regulator entirely, the Trump administration is virtually guaranteeing that this country will see a serious accident or other radiological release that will affect the health, safety and livelihoods of millions,' Lyman said. Recommended Reading What's next for advanced nuclear technology? Solve the daily Crossword
Yahoo
18 hours ago
- Yahoo
XRP Just Passed $3. Is $4 on the Horizon?
Key Points XRP has benefited from the more lax regulatory environment. The token runs on a strong network capable of processing hundreds, if not thousands, of transactions per second. Ripple's CEO, Brad Garlinghouse, thinks XRP can start taking share from international payment transactions. 10 stocks we like better than XRP › XRP (CRYPTO: XRP), the world's third-largest cryptocurrency, which has a market cap over $177 billion, recently passed $3. While the cryptocurrency continues to be volatile, XRP has had an epic run since President Donald Trump won the election last November, ushering in a new, more welcoming regulatory era for cryptocurrencies. XRP has benefited immensely. With the token hovering around the $3 level, as of this writing, is $4 on the horizon? What could catapult XRP higher One of the reasons XRP benefited from Trump's win so much is that the Trump administration installed new cabinet members to lead most regulatory agencies such as the Securities and Exchange Commission (SEC). In 2020, the SEC sued Ripple, the company behind XRP, and the company's co-founder and CEO for allegedly selling XRP as an unregistered security in 2013. The case had implications for the crypto sector and cast a negative light on XRP. While it looked like Ripple was heading for victory in the case, new leadership at the SEC expedited a resolution. Other new regulations have paved the way for an eventual SEC-approved spot-XRP exchange-traded fund, which would likely improve liquidity and broaden institutional interest in XRP. Ripple also continues to grow its business with mainstream banks and institutional traders. This year, the company acquired the prime brokerage Hidden Road, which it could use to integrate XRP within more mainstream finance activities. Furthermore, Ripple launched RLUSD, its own U.S.-dollar-backed stablecoin, which XRP serves as a bridge token for. A bridge token is a digital asset that allows for the transfer of value between different blockchain networks. Another way for XRP to draw interest would be to continue to drive a compelling use case with its network. XRP can currently process 1,500 transactions per second (TPS), making it ideal for cross-border payments. Other crypto networks boast even higher TPS, but XRP has an interesting ecosystem around it with Ripple, which has onboarded large mainstream financial clients and now has another bridge to mainstream finance with Hidden Road. RLUSD could present another opportunity for increased usage, and Ripple's CEO Brad Garlinghouse is optimistic that XRP can take share from international payment transactions. Garlinghouse specifically sees an opportunity to take share from the Society for Worldwide Interbank Financial Telecommunications (SWIFT). SWIFT helps financial institutions all over the world transmit payment instructions to one another, although Garlinghouse claims the error rate is still fairly high. He thinks XRP over time could capture 14% of SWIFT's volume. If it does, XRP would see significantly increased usage, likely driving demand for the token and therefore driving the price higher. Is $4 on the horizon? Cryptocurrencies are extremely volatile, which makes setting crypto price targets difficult, as there are no cash flows or earnings to value. That said, if the crypto sector stays hot, XRP could certainly benefit and shoot higher to $4. For sustained price increases and rerating against the sector, I think XRP would need to start fulfilling some of Garlinghouse's predictions, including greater use for international payment transactions and share stolen from SWIFT. But it's hard to know when that might start happening, if it does. After all, it's fairly common to hear about great use cases for a crypto network only to see no movement in price. That's why I am keeping my position in XRP small and speculative. The cryptocurrency certainly has significant potential, but it also faces significant risks. Should you invest $1,000 in XRP right now? Before you buy stock in XRP, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and XRP wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Bram Berkowitz has positions in XRP. The Motley Fool has positions in and recommends XRP. The Motley Fool has a disclosure policy. XRP Just Passed $3. Is $4 on the Horizon? was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
